Prostate Cancer - Results from #520

Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer 177Lu-PSMA-617 therapy. July 30, 2024

Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma. July 30, 2024

Cells in the Polyaneuploid Cancer Cell State are Pro-Metastatic. July 30, 2024

Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. July 30, 2024

GATA2 promotes castration-resistant prostate cancer development by suppressing IFN-β axis-mediated antitumor immunity. July 30, 2024

Kataegis associated mutational processes linked to adverse prostate cancer presentation in African men. July 30, 2024

Correlates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer. July 29, 2024

Do Prostate Imaging-Reporting and Data System (PIRADS) lesions predict holmium laser enucleation of prostate outcomes? July 29, 2024

Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors. July 29, 2024

Readability and Information Quality in Cancer Information From a Free vs Paid Chatbot. July 29, 2024

MRI-Targeted Prostate Fusion Biopsy: What Are We Missing outside the Target? Implications for Treatment Planning. July 29, 2024

Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer. July 29, 2024

What is the nature and impact of cognitive difficulties following hormonal treatments for prostate cancer?: An interpretative phenomenological analysis. July 26, 2024

Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study. July 26, 2024

A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24. July 26, 2024

Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study. July 26, 2024

Biochemical Relapse-Free Survival in Post-Prostatectomy Patients Receiving 18F-Fluciclovine-Guided Prostate Bed Only Radiation: Post-Hoc Analysis of a Prospective Randomized Trial. July 26, 2024

A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity. July 26, 2024

Body composition as a determinant of the therapeutic index with androgen signaling inhibition. July 26, 2024

Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by 18F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prospective July 25, 2024

Page 27 of 1436